Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M159,572Revenue $M11,202Net Margin (%)42.8Z-Score8.6
Enterprise Value $M162,831EPS $1.8Operating Margin %56.2F-Score7
P/E(ttm))38.7Cash Flow Per Share $4.3Pre-tax Margin (%)54.2Higher ROA y-yY
Price/Book11.810-y EBITDA Growth Rate %0Quick Ratio1.7Cash flow > EarningsN
Price/Sales13.15-y EBITDA Growth Rate %8.2Current Ratio2.1Lower Leverage y-yY
Price/Cash Flow17.4y-y EBITDA Growth Rate %47.7ROA % (ttm)29.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)58.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M1,536ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDJulian Robertson 2014-06-30 Add2.98%$65.48 - $83.02
($77.76)
$ 105.4736%Add 28.55%443,911
GILDJoel Greenblatt 2014-06-30 Buy 0.48%$65.48 - $83.02
($77.76)
$ 105.4736%New holding, 466853 sh.466,853
GILDRay Dalio 2014-06-30 Add0.06%$65.48 - $83.02
($77.76)
$ 105.4736%Add 41.22%349,821
GILDRonald Muhlenkamp 2014-06-30 Reduce-0.59%$65.48 - $83.02
($77.76)
$ 105.4736%Reduce -24.63%144,715
GILDVanguard Health Care Fund 2014-06-30 Reduce-0.21%$65.48 - $83.02
($77.76)
$ 105.4736%Reduce -39.79%1,633,700
GILDGeorge Soros 2014-06-30 Sold Out -0.04%$65.48 - $83.02
($77.76)
$ 105.4736%Sold Out0
GILDMariko Gordon 2014-06-30 Reduce-0.02%$65.48 - $83.02
($77.76)
$ 105.4736%Reduce -35.57%11,654
GILDJulian Robertson 2014-03-31 Add0.59%$68.55 - $83.95
($78.44)
$ 105.4734%Add 7.91%345,320
GILDRay Dalio 2014-03-31 Add0.12%$68.55 - $83.95
($78.44)
$ 105.4734%Add 541.42%247,721
GILDGeorge Soros 2014-03-31 Buy 0.04%$68.55 - $83.95
($78.44)
$ 105.4734%New holding, 50000 sh.50,000
GILDJohn Burbank 2014-03-31 Buy 0.01%$68.55 - $83.95
($78.44)
$ 105.4734%New holding, 3619 sh.3,619
GILDMario Gabelli 2014-03-31 Add$68.55 - $83.95
($78.44)
$ 105.4734%Add 31.65%44,240
GILDDaniel Loeb 2014-03-31 Sold Out -1.9%$68.55 - $83.95
($78.44)
$ 105.4734%Sold Out0
GILDJohn Griffin 2014-03-31 Sold Out -0.48%$68.55 - $83.95
($78.44)
$ 105.4734%Sold Out0
GILDVanguard Health Care Fund 2014-03-31 Reduce-0.46%$68.55 - $83.95
($78.28)
$ 105.4735%Reduce -41.41%2,713,300
GILDJulian Robertson 2013-12-31 Add1.52%$58.9 - $75.2
($69.65)
$ 105.4751%Add 25.84%320,001
GILDDaniel Loeb 2013-12-31 Add1.27%$58.9 - $75.2
($69.65)
$ 105.4751%Add 200%1,500,000
GILDRay Dalio 2013-12-31 Buy 0.02%$58.9 - $75.2
($69.65)
$ 105.4751%New holding, 38621 sh.38,621
GILDJohn Griffin 2013-12-31 Reduce-1.02%$58.9 - $75.2
($69.65)
$ 105.4751%Reduce -68.21%620,000
GILDJohn Hussman 2013-12-31 Sold Out -0.86%$58.9 - $75.2
($69.65)
$ 105.4751%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GILD Joel Greenblatt 2014-06-30466,8530.030.48New Buy
GILD Ray Dalio 2014-06-30349,8210.020.22+41.22%
GILD Julian Robertson 2014-06-30443,9110.0313.4+28.55%
GILD Mario Gabelli 2014-06-3049,17000.02+11.14%
GILD John Burbank 2014-06-303,77400.01+4.28%
GILD Jean-Marie Eveillard 2014-06-3040000
GILD Ronald Muhlenkamp 2014-06-30144,7150.012.1-24.63%
GILD Mariko Gordon 2014-06-3011,65400.04-35.57%
GILD Vanguard Health Care Fund 2014-06-301,633,7000.110.36-39.79%
GILD George Soros 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MILLIGAN JOHN FPresident and COO 2014-09-08Sell146,895$105.99-0.11view
Alton Gregg HEVP, Corp & Med Affairs 2014-09-02Sell33,000$108.58-2.5view
MARTIN JOHN CChairman and CEO 2014-09-02Sell140,625$108.64-2.55view
Whitley Richard JamesDirector 2014-09-02Sell5,000$108.1-2.06view
Carter Paul RutherfordEVP Commercial Ops 2014-08-26Sell10,000$106.16-0.27view
Washington Robin LEVP, CFO 2014-08-25Sell4,304$105.870view
Cogan John FrancisDirector 2014-08-21Sell5,000$101.094.73view
Washington Robin LEVP, CFO 2014-08-14Sell33,556$95.5610.79view
Carter Paul RutherfordEVP Commercial Ops 2014-08-08Sell16,728$91.5815.6view
MARTIN JOHN CChairman and CEO 2014-08-01Sell140,625$91.5315.67view

Press Releases about GILD :

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
Gilead Sciences: Up Over 1,100% And Still Cheap Sep 09 2014 
After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? Aug 27 2014 
Everything's Going Right for Gilead Sciences Aug 26 2014 
New Magic Formula Stocks From Joel Greenblatt: CBI, DAL, GILD, MNST, ROST, LUV Aug 18 2014 
Julian Robertson Buys Tableau Software, Facebook, Netflix, Sells Ulta Salon, EBay, EQT Aug 14 2014 
Creating Cures And Dividends Where None Existed Before With Gilead Sciences Jul 26 2014 
Analyzing Why Gilead Sciences is Still a Great Buy Jul 24 2014 
Why AbbVie Looks Like a Sell Jul 18 2014 
Why Gilead Sciences Will Grow to $100 Jul 18 2014 
Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Jul 06 2014 


More From Other Websites
6:23 am Gilead Sciences announces European Commission granted marketing authorization for co's... Sep 20 2014
IBD 50 Stocks Setting Up, Including These 5 Medicals Sep 19 2014
Most active Nasdaq-traded stocks Sep 19 2014
Why Gilead Sciences Could Gain 30% Sep 19 2014
Gilead's Zydelig Approved In EU; Imbruvica In Wings Sep 19 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the... Sep 19 2014
Gilead Down on Weak Simtuzumab Data and Sovaldi News Sep 18 2014
Gilead Sciences: Failed Trial Always a 'Long Shot' Sep 18 2014
Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% Sep 18 2014
CVS: One In 12 Hepatitis C Patients Not Adhering To $1,000/Day Pill Sep 17 2014
Gilead's Sovaldi Usage Fades As Hep-C Patients Await Rivals Sep 17 2014
Regeneron Gets Breakthrough Therapy Status for Eylea Sep 17 2014
Video: Gilead Stock Falls On These Drug Setbacks Sep 17 2014
Gilead Sciences: What to Make of Its Latest Failure? Sep 17 2014
[$$] Gilead Cancer Treatment Fails Sep 17 2014
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer Sep 17 2014
Gilead Sciences Sep 16 2014
Today's Market Thorns, Roses, and All Time Highs... Sep 16 2014
Stocks Rise Ahead Of Fed, Led By Biotech, Chip Names Sep 16 2014
Gilead (GILD) Slips on Generic Sovaldi Licensing Deals Sep 16 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK